Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics - Takeaways - MDSpire

Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics

  • By

  • Jinjin Li

  • Ziyi Yang

  • Liangzhong Liu

  • Fei Tang

  • Taihao Zheng

  • Chao Zhang

  • Yuan Peng

  • Zhenzhou Yang

  • Zhiming Zhou

  • Benxu Tan

  • Xiaoyue Zhang

  • January 3, 2026

  • 0 min

Share

  • 1

    Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer, particularly prevalent in nonsmoking Asian females.

  • 2

    EGFR mutations are common in LUAD, with targeted therapies like EGFR-TKIs improving survival, though effectiveness varies among patients.

  • 3

    High PD-L1 expression is linked to resistance against EGFR-TKIs, leading to shorter survival in patients with advanced EGFR-mutant LUAD.

  • 4

    Radiomics offers a noninvasive alternative to assess PD-L1 levels through imaging, potentially avoiding the risks of invasive biopsies.

  • 5

    An interpretable model was developed to predict PD-L1 expression in advanced EGFR-mutant LUAD patients using radiomic features and clinical data.

Original Source(s)

Forecasting PD-L1 Levels in Patients with Advanced EGFR-Mutated Lung Adenocarcinoma through NECT, CECT Radiomics, and Clinical Characteristics

  • by Jinjin Li, Ziyi Yang, Liangzhong Liu, Fei Tang, Taihao Zheng, Chao Zhang, Yuan Peng, Zhenzhou Yang, Zhiming Zhou, Benxu Tan, Xiaoyue Zhang

  • January 3, 2026

Related Content

Brachytherapy Stents Using 125Iodine for Lung Cancer Associated with Superior Vena Cava Syndrome

Who Decides When a Doctor Steps Back?

Cognitive decline, credentialing, and why “I’ll know” often isn’t enough.

Development of a CT-based comprehensive model with deep learning for differentiating pathological types of pulmonary ground-glass nodules